Reuters logo
BRIEF-Wave Life Sciences initiates clinical trial for lead program in Duchenne muscular dystrophy
November 6, 2017 / 12:22 PM / in 12 days

BRIEF-Wave Life Sciences initiates clinical trial for lead program in Duchenne muscular dystrophy

Nov 6 (Reuters) - Wave Life Sciences Ltd

* Wave Life Sciences initiates clinical trial for lead program in Duchenne muscular dystrophy (DMD)

* Wave Life Sciences Ltd - ‍data from phase 1 trial for WVE-210201 are expected in Q3 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below